Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“ASCO 26 Not all HR+/HER2 – early breast cancers behave the same.
New biomarker analysis from NATALEE suggests adjuvant ribociclib benefits were seen across ALL PAM50 subtypes, with a possible trend toward greater benefit in genomically higher-risk disease.
- 3022 tumor samples analyzed
- IDFS benefit maintained: HR 0.72 in biomarker cohort
Interesting signals:
- Luminal B, HER2 – enriched and basal-like tumors had worse prognosis vs Luminal A
- Ribociclib benefit remained consistent across subtypes
- Higher proliferation/genomic-risk signatures may predict greater benefit
- Exploratory gene-expression markers (eg CEACAM6, NOD2, GPX3) linked with enhanced RIB benefit
Takeaway: This reinforces CDK4/6 inhibition as a broad adjuvant strategy in HR+/HER2- EBC, while opening the door for future biomarker-driven personalization.
Abstract 501 – NATALEE biomarker analysis ASCO26.
Prognostic and predictive impact of baseline gene expression in adjuvant ribociclib + NSAI for HR+/HER2 – early breast cancer.
To which Long Nguyen, Medical Oncologist at Vietnam National Cancer Hospital, added:
“Or maybe we should test another biomarker.”
Title: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay
Authors: François-Clément Bidard, Grégoire Gessain, Thomas Bachelot, Lucie Frechin, Anne Vincent-Salomon, Damien Drubay, Jérôme Lemonnier, Thomas Walter, Frédérique Penault-Llorca, Anne-Laure Martin, Catherine Gaudin, Antoine Bichat, Farah Sassi, Sylvain Berlemont, Mariana Chavez-MacGregor, Hope S. Rugo, Cécile Badoual, Barbara Pistilli, Joana Ribeiro, Antonio Di Meglio, Magali Lacroix-Triki, Ines Vaz Luis, Marvin Lerousseau, Fabrice André
Other articles featuring Rishabh Jain and Long Nguyen on OncoDaily.
